Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Breast cancer marker

A marker, breast cancer technology, applied in the field of biomedicine, can solve the problems of breast cancer cell loss, loose cell connection, easy to fall off, etc.

Active Publication Date: 2018-03-09
GUANGDONG MEDICAL UNIV
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Breast cancer in situ is not fatal; however, because breast cancer cells lose their normal cell properties, the cells are loosely connected and prone to detachment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Breast cancer marker
  • Breast cancer marker
  • Breast cancer marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Using lectin affinity chromatography combined with high performance liquid chromatography / mass spectrometry to identify differentially expressed glycoproteins in the plasma of breast cancer patients in order to obtain breast cancer candidate markers.

[0052] 1. Sample source and information

[0053]Plasma samples were collected from Dongguan Sixth People's Hospital and Zhongshan Xiaolan Hospital. According to the seventh edition of the American Joint Commission for Cancer Staging (AJCC) clinical staging criteria for breast cancer, they were divided into Stage0: TisN0M0; StageⅠ: T1N0M0; StageⅡA: T0N1M0, T1N1M0, T2N0M0; StageⅡB: T2N1M0, T3N0M0; StageⅢA: T0N2M0, T1N2M0, T2N2M0, T3N1-2M0; StageⅢB: T4N0-2M0; StageⅢC: any T N3M0; StageⅣ: any T any N M1stage. Among them, Tis is carcinoma in situ, T stands for primary tumor, N stands for regional lymph nodes, and M stands for distant metastasis. Breast cancer samples are grouped here according to their sex, age and number of ...

Embodiment 2

[0070] The above candidate markers were further verified by western blot.

[0071] In order to further verify the expression changes of these three proteins, the inventors used W estern blo t The protein expression changes in 52 plasma samples of 19 cases of BC1, 9 cases of BC2, 8 cases of BC3, 4 cases of BC4 and 12 healthy persons were detected. For each set of Wes tern blo t In the experiment, healthy control H1 was selected as a standard, and other bands were quantified using WB grayscale analysis software, and each protein band was quantified by densitometry. The result is as Figure 6 As shown, Serotransferrin protein expression was down-regulated in Stage1 group compared with healthy control group (consistent with mass spectrometry data); Plasma protease C1 inhibitor was significantly down-regulated in Stage4 group compared with healthy control group (inconsistent with mass spectrometry data); SerpinB4 Compared with the healthy control group and Stage1 group, it wa...

Embodiment 3

[0074] The above candidate markers were further verified by reverse lectin ELISA (Reverse-Lectin ELISA). The following is the Reverse-Lectin ELISA test procedure.

[0075] Prepare 4 μg / ml of AAL2 in 15 mmol / l sodium carbonate buffer solution (pH 9.6), coat ELISA 96-well plate, 100 μl per well, overnight at 4°C; the next day, discard the coating solution and wash once with PBST; wash once with 5 % Skimmed milk powder blocking solution (5% skimmed milk powder dissolved in PBST solution, pH 7.4) 300 μl per well for blocking incubation, overnight at 4°C; discard the blocking solution, add 300 μl washing solution to each well, wash five times, 3 min each time, Pat the plate dry on filter paper; PBST dilutes the appropriate multiple of plasma samples (according to the pre-experimental dilution results), add 100 μl to each well, incubate at room temperature for 1 h; discard the samples, add 300 μl PBST washing solution to each well, wash five times, each Pat the plate dry on filter ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of biomedicine detection, and provides a breast cancer marker which comprises at least one of glycoproteins such as serum transferrin with end N-acetylglucosamine sugar, plasma protease C1 inhibiting factors with end N-acetylglucosamine sugar and serine protease inhibitors B4 with end N-acetylglucosamine sugar. The quantity of any one, two or all of the glycoproteins in samples to be detected is detected, the breast cancer marker can judge or help to judge occurrence and / or development of breast cancers, and single or any combination of the glycoproteins canserve as markers for screening or auxiliary screening diagnosis of the breast cancers.

Description

technical field [0001] The present invention relates to the field of biomedicine, in particular, to a disease detection marker, and more particularly, to a breast cancer marker. Background technique [0002] Breast cancer is a malignant tumor that occurs in the glandular epithelial tissue of the breast. The incidence of breast cancer worldwide has been on the rise since the late 1970s. According to the incidence data of breast cancer released by the National Cancer Center and the Bureau of Disease Control and Prevention of the Ministry of Health in 2012, the incidence of breast cancer in the national tumor registration area ranks first among female malignant tumors. [0003] According to the American Joint Commission for Cancer Staging (AJCC) seventh edition clinical staging criteria for breast cancer, breast cancer can be divided into Stage0: TisN0M0; StageⅠ: T1N0M0; StageⅡA: T0N1M0, T1N1M0, T2N0M0; StageⅡB: T2N1M0 , T3N0M0; StageⅢA: T0N2M0, T1N2M0, T2N2M0, T3N1-2M0; Stag...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574G01N33/68G01N33/543
CPCG01N33/543G01N33/57415G01N33/57484G01N33/6893G01N2800/365
Inventor 梁一关鑫黄壮霖
Owner GUANGDONG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com